Show simple item record

Biochemical Diagnosis and Localization of Pheochromocytoma

dc.contributor.authorGrossman, Ashleyen_US
dc.contributor.authorPacak, Karelen_US
dc.contributor.authorSawka, Annaen_US
dc.contributor.authorLenders, Jacques W. M.en_US
dc.contributor.authorHarlander, Debraen_US
dc.contributor.authorPeaston, Robert T.en_US
dc.contributor.authorReznek, Rodneyen_US
dc.contributor.authorSisson, James C.en_US
dc.contributor.authorEisenhofer, Graemeen_US
dc.date.accessioned2010-06-01T18:55:08Z
dc.date.available2010-06-01T18:55:08Z
dc.date.issued2006-08en_US
dc.identifier.citationGROSSMAN, ASHLEY; PACAK, KAREL; SAWKA, ANNA; LENDERS, JACQUES W. M . ; HARLANDER, DEBRA; PEASTON, ROBERT T . ; REZNEK, RODNEY; SISSON, JAMES; EISENHOFER, GRAEME (2006). "Biochemical Diagnosis and Localization of Pheochromocytoma." Annals of the New York Academy of Sciences 1073(1 Pheochromocytoma: First International Symposium ): 332-347. <http://hdl.handle.net/2027.42/72111>en_US
dc.identifier.issn0077-8923en_US
dc.identifier.issn1749-6632en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72111
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17102103&dopt=citationen_US
dc.description.abstractPheochromocytomas can have a highly variable presentation, making diagnosis challenging. To think of the tumor represents the crucial initial step, but establishing the diagnosis requires biochemical evidence of excessive catecholamine production and imaging studies to localize the source. Currently, however, there exist no generally agreed upon guidelines based on which tests and testing algorithms should be used to confirm and locate or exclude a suspected pheochromocytoma. Choice of biochemical tests and imaging studies instead usually depends on institutional experience. At the First International Symposium on Pheochromocytoma (ISP2005), held in Bethesda in October 2005, a panel of experts and patient representatives discussed current problems and available options for tumor diagnosis and localization and formulated recommendations, which were subsequently agreed upon by those in attendance at the meeting. This article summarizes the discussion and recommendations derived from that session.en_US
dc.format.extent210611 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights2006 New York Academy of Sciencesen_US
dc.subject.otherPheochromocytomaen_US
dc.subject.otherBiochemical Diagnosisen_US
dc.subject.otherMetanephrinesen_US
dc.subject.otherCatecholaminesen_US
dc.subject.otherLocalizationen_US
dc.subject.otherComputed Tomographyen_US
dc.subject.otherMagnetic Resonance Imagingen_US
dc.subject.otherMIBGen_US
dc.subject.otherPositron Emission Tomographyen_US
dc.titleBiochemical Diagnosis and Localization of Pheochromocytomaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelScience (General)en_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Radiology, University of Michigan Hospitals, Ann Arbor, Michigan 48109, USAen_US
dc.contributor.affiliationotherDepartment of Endocrinology, St. Bartholomew's Hospital, West Smithfield, London, UKen_US
dc.contributor.affiliationotherReproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USAen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Toronto, Toronto, Ontario, Canadaen_US
dc.contributor.affiliationotherDepartment of General Internal Medicine, St. Radboud University Hospital, Nijmegen, the Netherlandsen_US
dc.contributor.affiliationotherPheochromocytoma Support Group, Camden, New York 13316, USAen_US
dc.contributor.affiliationotherDepartment of Clinical Biochemistry, Freeman Hospital, Newcastle upon Tyne, UKen_US
dc.contributor.affiliationotherDivision of Radiology, St. Bartholomew's Hospital, West Smithfield, London, UKen_US
dc.contributor.affiliationotherClinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USAen_US
dc.identifier.pmid17102103en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72111/1/annals.1353.038.pdf
dc.identifier.doi10.1196/annals.1353.038en_US
dc.identifier.sourceAnnals of the New York Academy of Sciencesen_US
dc.identifier.citedreferencePlatts, J.K., P.J. Drew & J.N. Harvey. 1995. Death from phaeochromocytoma: lessons from a post-mortem survey. J. Roy. Coll. Physicians Lond. 29: 299 – 306.en_US
dc.identifier.citedreferenceLo, C.Y. et al. 2000. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am. J. Surg. 179: 212 – 215.en_US
dc.identifier.citedreferenceMcNeil, A.R. et al. 2000. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust. N. Z. J. Med. 30: 648 – 652.en_US
dc.identifier.citedreferenceKaltsas, G.A., D. Papadogias & A.B. Grossman. 2004. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front. Horm. Res. 31: 61 – 75.en_US
dc.identifier.citedreferenceSjoerdsma, A. et al. 1959. Studies on the biogenesis and metabolism of norepinephrine in patients with pheochromocytoma. J. Clin. Invest. 38: 31 – 38.en_US
dc.identifier.citedreferenceCrout, J.R. & A. Sjoerdsma. 1964. Turnover and metabolism of catecholamines in patients with pheochromocytoma. J. Clin. Invest. 43: 94 – 102.en_US
dc.identifier.citedreferenceEisenhofer, G. et al. 2003. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr. Pathol. 14: 193 – 212.en_US
dc.identifier.citedreferenceEisenhofer, G. et al. 1999. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N. Engl. J. Med. 340: 1872 – 1879.en_US
dc.identifier.citedreferenceRaber, W. et al. 2000. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch. Intern. Med. 160: 2957 – 2963.en_US
dc.identifier.citedreferenceLenders, J.W. et al. 2002. Biochemical diagnosis of pheochromocytoma: which test is best ? JAMA 287: 1427 – 1434.en_US
dc.identifier.citedreferenceSawka, A.M. et al. 2003. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J. Clin. Endocrinol. Metab. 88: 553 – 558.en_US
dc.identifier.citedreferenceSawka, A.M. et al. 2004. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr. Disord. 4: 2.en_US
dc.identifier.citedreferenceUnger, N. et al. 2006. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur. J. Endocrinol. 154: 409 – 417.en_US
dc.identifier.citedreferenceGardet, V. et al. 2001. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J. Hypertens. 19: 1029 – 1035.en_US
dc.identifier.citedreferenceGerlo, E.A. & C. Sevens. 1994. Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin. Chem. 40: 250 – 256.en_US
dc.identifier.citedreferenceDavidson, D.F. 2002. Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines. Ann. Clin. Biochem. 39: 557 – 566.en_US
dc.identifier.citedreferenceGuller, U. et al. 2006. Detecting pheochromocytoma: defining the most sensitive test. Ann. Surg. 243: 102 – 107.en_US
dc.identifier.citedreferenceSawka, A.M. et al. 2004. The economic implications of three biochemical screening algorithms for pheochromocytoma. J. Clin. Endocrinol. Metab. 89: 2859 – 2866.en_US
dc.identifier.citedreferenceBrown, M.J. & D.J. Allison. 1981. Renal conversion of plasma DOPA to urine dopamine. Br. J. Clin. Pharmacol. 12: 251 – 253.en_US
dc.identifier.citedreferenceEisenhofer, G. et al. 2005. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J. Clin. Endocrinol. Metab. 90: 2068 – 2075.en_US
dc.identifier.citedreferenceRoss, G.A. et al. 1993. Plasma and 24 h-urinary catecholamine concentrations in normal and patient populations. Ann. Clin. Biochem. 30 ( Pt. 1 ): 38 – 44.en_US
dc.identifier.citedreferenceSawka, A.M. et al. 2005. Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: can specificity be improved by adjustment for age ? BMC Endocr. Disord. 5: 1.en_US
dc.identifier.citedreferenceEisenhofer, G. et al. 1995. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism ? Clin. Sci. (Lond.) 88: 533 – 542.en_US
dc.identifier.citedreferenceEisenhofer, G. et al. 2003. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J. Clin. Endocrinol. Metab. 88: 2656 – 2666.en_US
dc.identifier.citedreferenceBrown, M.J. et al. 1981. Increased sensitivity and accuracy of phaeochromocytoma diagnosis achieved by use of plasma-adrenaline estimations and a pentolinium-suppression test. Lancet 1: 174 – 177.en_US
dc.identifier.citedreferenceBravo, E.L. et al. 1981. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N. Engl. J. Med. 305: 623 – 626.en_US
dc.identifier.citedreferenceMulinari, R.A. et al. 1987. The clonidine test for the diagnosis of pheochromocytoma: the usefulness of urinary metanephrine measurements. Braz. J. Med. Biol. Res. 20: 43 – 46.en_US
dc.identifier.citedreferenceNeumann, H.P. et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346: 1459 – 1466.en_US
dc.identifier.citedreferenceAmar, L. et al. 2005. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 23: 8812 – 8818.en_US
dc.identifier.citedreferenceRemine, W. et al. 1974. Current management of pheochromocytoma. Ann. Surg. 179: 740 – 748.en_US
dc.identifier.citedreferenceTroncone, L. et al. 1990. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG): 5 years of experience. Eur. J. Nucl. Med. 16: 325 – 335.en_US
dc.identifier.citedreferencePeppercorn, P.D., A.B. Grossman & R.H. Reznek. 1998. Imaging of incidentally discovered adrenal masses. Clin. Endocrinol. (Oxford) 48: 379 – 388.en_US
dc.identifier.citedreferenceGrumbach, M.M. et al. 2003. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann. Intern. Med. 138: 424 – 429.en_US
dc.identifier.citedreferenceEisenhofer, G. et al. 2005. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin. Chem. 51: 735 – 744.en_US
dc.identifier.citedreferenceFrancis, I. & M. Korobkin. 1996. Pheochromocytoma. Adv. Uroradiol. 34: 1101 – 1112.en_US
dc.identifier.citedreferenceGoldstein, R.E. et al. 1999. Clinical experience over 48 years with pheochromocytoma. Ann. Surg. 229: 755 – 764; discussion 764–766.en_US
dc.identifier.citedreferenceSahdev, A. et al. 2005. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur. Radiol. 15: 85 – 92.en_US
dc.identifier.citedreferenceMukherjee, J.J. et al. 1997. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 202: 227 – 231.en_US
dc.identifier.citedreferenceQuint, L.E. et al. 1987. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 165: 89 – 93.en_US
dc.identifier.citedreferenceVarghese, J.C. et al. 1997. MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Clin. Radiol. 52: 603 – 606.en_US
dc.identifier.citedreferenceFuruta, N. et al. 1999. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int. J. Urol. 6: 119 – 124.en_US
dc.identifier.citedreferenceIlias, I., B. Shulkin & K. Pacak. 2005. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol. Metab. 16: 66 – 72.en_US
dc.identifier.citedreferenceMiskulin, J. et al. 2003. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma ? Surgery 134: 918 – 922; discussion 922–923.en_US
dc.identifier.citedreferenceHoegerle, S. et al. 2002. Pheochromocytomas: detection with 18F DOPA whole body PET: initial results. Radiology. 222: 507 – 512.en_US
dc.identifier.citedreferencePacak, K. et al. 2001. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38: 6 – 8.en_US
dc.identifier.citedreferenceShulkin, B.L. et al. 1999. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Nucl. Med. 212: 35 – 41.en_US
dc.identifier.citedreferenceMann, G.N. et al. 2006. [(11)C]metahydroxyephedrine and [(18)F]Fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann. Surg. Oncol. 13: 187 – 197.en_US
dc.identifier.citedreferenceTrampal, C. et al. 2004. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 230: 423 – 428.en_US
dc.identifier.citedreferenceMediavilla Garcia, J.D. et al. 1999. A comparative study of 9 cases of adrenal pheochromocytoma and 11 cases of extra-adrenal pheochromocytoma. Rev. Clin. Esp. 199: 343 – 348.en_US
dc.identifier.citedreferenceKaltsas, G. et al. 2001. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86: 895 – 902.en_US
dc.identifier.citedreferenceChew, S.L. et al. 1994. Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay. Q. J. Med. 87: 49 – 54.en_US
dc.identifier.citedreferencePacak, K. et al. 2001. A “pheo” lurks: novel approaches for locating occult pheochromocytoma. J. Clin. Endocrinol. Metab. 86: 3641 – 3646.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.